FierceBiotechQwen · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 03:46:00(美东 09-08 15:46)时区推断·⟳ 抓取 18:56:45·⚡ 决策 09-09 23:24:14 +4h27m·48.0 天前
Schrödinger 出资两个临床前小分子项目，联合外部资本成立免疫炎症 NewCo「Tectora Therapeutics」并附 5,500 万美元 A 轮，自身换取少数股权+未来里程碑与特许权
跨源查重无重复；证据显示该 NewCo 是 Schrödinger 已多次公开阐述的资本轻化发现合作模式（Nimbus/Morphic/Ajax/Petra 等 7 次交易）的又一次例行落地，而非新增事实：出资标的为两个靶点未披露的临床前项目，对价为比例未披露的少数股权加长期里程碑/royalty，无 upfront 现金、无指引调整、无 2026 收入影响。按 5,500 万美元 A 轮量级估算权益价值 <1% 市值（14.49 亿美元），最早变现要等到多年后的退出交易。市场当日亦未据此重定价（盘中 -3.3%，量比 1.07）。方向不明确、无短窗 edge，故不做；同时不存在公司级新增净利空，不输出 risk_signals。
📄 原文FierceBiotech↗ 原文
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
Schrödinger has announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55…
不做 Schrödinger, Inc.（SDGR.US）
事件是公司已公开既定战略（不自行推进内部项目进临床、改由合作方/NewCo 承接）的例行落地：换出两个靶点未披露的临床前项目 SDGR-4594/SDGR-8139，换回比例未披露的少数股权+长期里程碑/royalty，无 upfront 现金、无指引修订；按 Tectora 5,500 万美元 A 轮量级估算权益价值 <1% 的 14.49 亿美元市值，1–10 个交易日窗口内无可量化增量，最早变现要等多年后的退出交易。盘面当日 -3.3%、量比 1.07，市场未重定价。…
不做 Tectora Therapeutics（N/A）
隐身运营的私营 NewCo，无主上市、ADR 或跟踪单一股票的杠杆产品，结构上不存在可交易载体
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实：Schrödinger 把两个临床前小分子项目（SDGR-4594、SDGR-8139，靶点未披露）注入新设免疫炎症 NewCo Tectora，Tectora 带 5,500 万美元 A 轮，SDGR 换少数股权+未来里程碑/royalty，无现金对价、无指引变化。影响链：短期 SDGR 损益/现金流不变，反而把后续开发支出外部化；长期是既有『平台+联合创立』期权价值的又一次复制（过去 10 年 7 次重大交易、近 7 亿美元现金、约 50 亿美元潜在里程碑）。价格与证据：SDGR 现价 19.37 美元、市值 14.49 亿美元，20 日 +6.7%、13 周轨迹 100→137（上行），事件当日盘中 -3.3%、量比 1.07，无同向重定价，也无事件前抢跑迹象；按 A 轮量级估算权益占比 <1% 市值，1–10 日窗口内无 materiality。结论：例行战略落地、增量不可量化、无短窗 edge，AVOID；Tectora 为私营不可交易，靶点未披露导致竞品/跨市场映射不成立。
🔎 新鲜度:最早出现 2026-09-09 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次公告不含对 Schrödinger 近期收入、现金流或 2026 指引的任何可量化增量，权益对价按 5,500 万美元 A 轮量级估算 <1% 市值
- NewCo/联合创立模式是公司 2025Q3 以来已反复公开阐述的既定战略，属明牌落地而非预期差
- 价值兑现依赖多年后的临床进展与退出交易，无法在 1–10 个交易日的交易窗口内表达
主要风险
- 若后续官方新闻稿披露 Schrödinger 持股比例、upfront 现金或明确里程碑金额显著高于估算（例如数千万美元级现金流入），materiality 判断需重估
- 反向风险：换出两个内部项目意味着自有管线进一步变薄，若市场把此类分拆解读为『资产外流/自身研发收缩』，短期可能构成小幅估值压制（当日 -3.3% 尚不能归因于此）
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-05-05 · 影响 invalidates
2026Q1 电话会明确『施罗德不将自有项目推进至临床，而是早期合作』，并称过去 10 年联合创立公司已产生 7 次重大交易、近 7 亿美元现金、潜在里程碑约 50 亿美元、15 个项目 royalty；2025Q3 会亦称除 SGR1505/SGR3515 外不再独立推进内部项目进临床——本次 NewCo 正是该已公开战略的落地，构成对做多逻辑的直接削弱（无预期差）
检索:Schrödinger 不再自行推进内部项目进临床 早期合作 NewCo 战略 研发费用 2026 原文 ↗ - 做多前查反向 · 来源 filing · 日期 2026-09-09 · 影响 weakens
近 20 日 +6.7%、13 周指数化轨迹 100→137 属多周上行（非事件前 1–2 日突放量大涨），20 日波动率 4.25%、量比 1.07、距 60 日高 -6.4%；事件当日盘中 -3.3%，无同向重定价，既无抢跑泄露也无正向定价，说明市场视其为非事件
检索:SDGR 事件前是否抢跑/异动 近20日走势 量比 距高点 - 做空前查反向 · 来源 kb_search · 日期 2026-08-06 · 影响 none
Morgan Stanley 2Q26 研报口径为『Ajax 里程碑推动收入超预期、药物发现指引上调、ACV 增长 27%』，未检索到与本次公告相关的砍单、下修或监管负面；做空同样缺乏明确强空催化（换出临床前资产属既定轻资本战略，不构成实质净损害），故不开空
检索:Schrödinger 近期利空 指引下调 现金 里程碑 减少 研发收缩 风险 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例层缺失不改变结论：本事件在 materiality（<1% 市值、无现金）与时效（多年后兑现）两个维度都不具备 1–10 日交易价值，AVOID 不依赖先例
方向:内部 KB/纪要显示，Schrödinger 联合创立公司（Nimbus、Morphic、Ajax、Petra 等）过去 10 年产生 7 次重大交易、累计近 7 亿美元现金与约 50 亿美元潜在里程碑，但价值兑现点都在后续退出/授权交易，而非 NewCo 成立公告当日；成立类公告本身不构成方向性价格催化
涨幅量级:无高相似、首发锚干净且带真实日线的可计量样本，故不校准 tp/sl 幅度
形态:不适用（无可计量面板）；仅从当日盘面看无冲高回落式的『见光死』，因为根本没有正向反应
工具执行结果 · 成功 6 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 97 ms
{"result": "search_processed_events:agent query=`schrödinger spin out biotech equity milestone royalty | schrödinger tectora therapeutics 成立 | sdgr 分拆 newco 免疫 早期小分子项目 sdgr-4594 sdgr-8139 | tectora therapeutics $55 million series`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 28.7/72 小时、1535 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 - stock_quote 成功 stock_tools HTTP · 1,624 ms
{ - fetch_decision_experience 成功 stock_tools HTTP · 13 ms
{ - kb_search 成功 stock_tools HTTP · 1,109 ms
{ - search_case_library 成功 stock_tools HTTP · 20 ms
{"result": "search_case_library「SDGR.US」无历史决策命中(我们过去没在这些标的上决策过,或历史尚未回填)。\n◆ SDGR.US：相关历史决策 12 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过"} - kb_search 成功 stock_tools HTTP · 683 ms
{
原文全文
展开原文 · 2,579 字
Schrödinger has announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round in tow.
For the launch, Schrödinger contributed two early-stage small molecule programs, in turn winning an equity stake in Tectora and eligibility to receive future milestones and royalties.
Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s computational platform to help advance these candidates to the clinic.
“Schrödinger is a software company, but it has stakes in quite a lot of really exciting programs, and this is an expansion of that,” Karen Akinsanya, Ph.D., Schrödinger’s President of Therapeutics R&D, told Fierce. “We intend to keep expanding these discovery collaborations.”
Tectora will be focused on developing differentiated oral medicines for immunology and inflammation and will operate in stealth, Akinsanya told Fierce. The two small molecule programs, SDGR-4594 and SDGR-8139, bestowed upon Tectora by Schrödinger, are currently undisclosed, but are products of Schrödinger’s computational platform, she said.
The company's approach revolves around a physics-based computational chemistry platform that has the ability to predict potency, selectivity, solubility and permeability, according to Akinsanya. It hinges on atomistic modeling, which is a simulation technique to study the behavior of molecules by tracking individual atoms, the basic building blocks of all matter in the universe, and their interactions.
“The motivation is to have dedicated capital going towards these programs [SDGR-4594 and SDGR-8139] for their future development, but also to allow a dedicated team of experts around the science behind the programs,” Akinsanya said.
New York-headquartered Schrödinger has a deep history of founding and building biotech companies.
Schrödinger’s Nimbus Therapeutics, a Fierce15 winner in 2013, has racked up a number of Big Pharma deals, including a $1.3 billion pact with Eli Lilly on an oral obesity therapy, and a $4 billion sale to Takeda for its tyrosine kinase 2 (TYK2) program, zasocitinib, which recently enjoyed a positive phase 3 data readout in difficult-to-treat psoriasis.
In July 2024, meanwhile, Eli Lilly bought Schrödinger’s Morphic and an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio for $3.2 billion. Ajax Therapeutics, recently acquired by Eli Lilly in a potential $2.3 billion deal, was co-founded by Schrödinger in 2019 to develop small molecules for hematologic malignancies.
For the launch, Schrödinger contributed two early-stage small molecule programs, in turn winning an equity stake in Tectora and eligibility to receive future milestones and royalties.
Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s computational platform to help advance these candidates to the clinic.
“Schrödinger is a software company, but it has stakes in quite a lot of really exciting programs, and this is an expansion of that,” Karen Akinsanya, Ph.D., Schrödinger’s President of Therapeutics R&D, told Fierce. “We intend to keep expanding these discovery collaborations.”
Tectora will be focused on developing differentiated oral medicines for immunology and inflammation and will operate in stealth, Akinsanya told Fierce. The two small molecule programs, SDGR-4594 and SDGR-8139, bestowed upon Tectora by Schrödinger, are currently undisclosed, but are products of Schrödinger’s computational platform, she said.
The company's approach revolves around a physics-based computational chemistry platform that has the ability to predict potency, selectivity, solubility and permeability, according to Akinsanya. It hinges on atomistic modeling, which is a simulation technique to study the behavior of molecules by tracking individual atoms, the basic building blocks of all matter in the universe, and their interactions.
“The motivation is to have dedicated capital going towards these programs [SDGR-4594 and SDGR-8139] for their future development, but also to allow a dedicated team of experts around the science behind the programs,” Akinsanya said.
New York-headquartered Schrödinger has a deep history of founding and building biotech companies.
Schrödinger’s Nimbus Therapeutics, a Fierce15 winner in 2013, has racked up a number of Big Pharma deals, including a $1.3 billion pact with Eli Lilly on an oral obesity therapy, and a $4 billion sale to Takeda for its tyrosine kinase 2 (TYK2) program, zasocitinib, which recently enjoyed a positive phase 3 data readout in difficult-to-treat psoriasis.
In July 2024, meanwhile, Eli Lilly bought Schrödinger’s Morphic and an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio for $3.2 billion. Ajax Therapeutics, recently acquired by Eli Lilly in a potential $2.3 billion deal, was co-founded by Schrödinger in 2019 to develop small molecules for hematologic malignancies.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。